Advanced Search
Share
May - June 2013 Erratum in «High rate of virologic supression with darunavir/ritonavir plus...
Journal Information
Previous article | Next article
Vol. 17. Issue 3.
Pages 387 (May - June 2013)
Export reference
Share
Share
Print
Download PDF
More article options
Statistics
Vol. 17. Issue 3.
Pages 387 (May - June 2013)
Erratum
DOI: 10.1016/j.bjid.2013.05.001
Open Access
Erratum in «High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil»
Visits
3734
Download PDF
José Ernesto Vidala,b,
Corresponding author
josevibe@gmail.com

Corresponding author: Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, Avenida Doutor Arnaldo, Cerqueira, César, São Paulo, SP, 01246-000, Brazil. Tel.: +55 11 38961200; fax: +55 11 38961200.
, Alice Tung Wan Songa, Maria Laura Matosa, Daniel Bartmanna, Guilherme dos Anjosa, Érique José Peixoto de Mirandaa, Ângela Carvalho Freitasa, Mirian de Freitas Dalbena, Claudinei Santanac, Aluísio Cotrim Seguradoa, Cláudia Cortese Barretod,e, Adrián Vladimir Hernándezf
a Department of Infectious Diseases, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
b Department of Infectious Diseases, Instituto de Infectologia Emílio Ribas, São Paulo, SP, Brazil
c Pharmacy School, Universidade de São Paulo, São Paulo, SP, Brazil
d Pro-Blood Foundation/Blood Center of São Paulo (FPS/HSP), Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
e Laboratory of Medical Investigation in Dermatology and Immunodeficiencies – LIM-56, Department of Dermatology, Medical School, Universidade de São Paulo, São Paulo, SP, Brazil
f Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, USA
Related content
High rate of virologic suppression with darunavir/ritonavir plus optimized background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil
Braz J Infect Dis. 2013;17:41-710.1016/j.bjid.2012.08.022
José Ernesto Vidal, Alice Tung Wan Song, Maria Laura Matos, Daniel Bartmann, Guilherme dos Anjos, Érique José Peixoto de Miranda, Ângela Carvalho Freitas, Mirian de Freitas Dalben, Claudinei Santana, Aluísio Cotrim Segurado, Cláudia Cortese Barreto, Adrián Vladimir Hernández
This item has received
3734 Visits

Under a Creative Commons license
Article information
Full Text
Download PDF
Statistics
Full Text

In the article “High rate of virologic supression with darunavir/ritonavir plus optimazed background therapy among highly antiretroviral-experienced HIV-infected patients: results of a prospective cohort study in São Paulo, Brazil”, published in Braz J Infect Dis. 2013 Feb;17(1):41-7, please consider the following corrections:

Page 43, Table 1, line 18, “Previous use of NRTI, NNRTI and PIs: 87 (95)” should read as “Previous use of NRTI, NNRTI and PIs: 92 (100%)”.

Page 43, Results section, lines 28-31, “Tenofovir was the most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive: 16 (17.4%), intermediate resistance: 8 (8.7%), and resistance: 68 (73.9%).” should read as “All patients received lamivudine and their genotyping evaluation were resistant in all cases. Tenofovir was the second most frequent NRTI used (n=83, 90.2%) and its genotyping evaluation were: sensitive:14 (16.9%), intermediate resistance: 7 (8.4%), and resistance: 62 (74.7%).”

DOI of the original article: http://dx.doi.org/10.1016/j.bjid.2012.08.022

Subscribe to our newsletter

Publish in
The Brazilian Journal of Infectious Diseases
Download PDF
The Brazilian Journal of Infectious Diseases
Article options
Tools